At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 106 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
In Brief
A Phase 3 clinical trial evaluating Nivolumab and Ipilimumab for Melanoma. Completed, enrolled 106 participants across 16 sites in 4 countries.
Detailed Summary
This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesAustralia, France, Italy, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionOct 2017
Study CompletionOct 2019
TodayJul 2026
First PostedSep 19, 2016
Enrollment StartOct 27, 2016
Primary CompletionOct 23, 2017
Study CompletionOct 25, 2019
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 9.8 years ago
Interventions
Nivolumabbiological
-Specified dose on specified days
Ipilimumabbiological
-Specified dose on specified days